ApTOLL for the Treatment of COVID-19

• Status: Recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

There is a clear and urgent medical need of developing new medicinal products for COVID-19 since there are poor pharmacological tools to block the progression of patients to cytokine storm syndrome (CSS). To this aim, this Phase Ib clinical study (APTACOVID) pretends to determine whether ApTOLL, in combination with the standard of care, is safe and shows any biological effect) in those patients infected with SARS-CoV-2 who are not developed CSS yet.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Macarena Hernández Jiménez
• Collaborator: Centro para el Desarrollo Tecnológico Industrial

Criteria

Inclusion Criteria:

1. Men or women with age ≥18 and ≤85 years.

2. In case of women of childbearing potential (WOCBP), they should confirm menstrual period and a negative highly sensitive urine or serum pregnancy test to be included.

3. Laboratory-confirmed SARS-CoV-2 infection.

4. Informed consent obtained .

5. Hypoxia (SpO2<95%).

6. Documented lung opacities/infiltrates.

7. Confirmed hyperinflammation.

Exclusion Criteria:

1. Onset of symptoms of COVID-19 >14 days.

2. Pregnant or nursing (lactating) women.

3. Hospitalized >10 days for COVID-19.

4. Need of high concentration non-rebreather mask, high-flow nasal cannula , non-invasive mechanical ventilation or invasive mechanical ventilation.

5. Systolic blood pressure < 90 mmHg.

6. Serious concomitant illness.

7. Recent treatment with cell-depleting therapies.

8. Enrolled in another clinical trial.

9. Severe renal dysfunction.

10. In the opinion of the investigator, unable to comply with the requirements to participate in the study.